var data={"title":"Gadoteridol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Gadoteridol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6248?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=gadoteridol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Gadoteridol: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49334650\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gadolinium-Based Contrast Agents Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is requiring a new class warning, new Medication Guide, and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) regarding gadolinium remaining in patients' bodies, including the brain, for months to years after receiving these drugs. However, because gadolinium retention has not been directly linked to adverse health effects in patients with normal kidney function, the FDA has concluded that the benefit of all approved GBCAs continues to outweigh any potential risks.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Health care providers should consider the retention characteristics of each agent when choosing a GBCA for patients who may be at higher risk for gadolinium retention, including those requiring multiple lifetime doses, pregnant women, children, and patients with inflammatory conditions. Although providers should minimize repeated GBCA imaging studies when possible, particularly closely spaced MRI studies, necessary GBCA MRI scans should not be avoided or deferred. Health care providers should ensure that patients carefully read the new Medication Guide before receiving a GBCA.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Further information can be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm&amp;token=Do7F8mUMHZ5/s1VO2ToSVQc0FIvxuJct8s2XQAmrP6Zclph1jTE4ohbEGIUswzhaMGIPSHysMdF12NhZ7JwyN2R2Gou2JaOgN/abp607dqC+GD0vx8r77GARzw9XI5at9GGki/68NHngWSah5+Qw3g==&amp;TOPIC_ID=8886\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm589580.htm</a>.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gadolinium-Based Contrast Agents for MRI Safety Review</span>\n      <span class=\"collapsible-date\">May 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA identified no evidence to date that gadolinium retention in the brain from any of the gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI) is harmful, including GBCAs associated with higher retention of gadolinium, and therefore, restricting GBCA use is not warranted at this time. All GBCAs may be associated with some gadolinium retention in the brain and other body tissues. The FDA will continue to assess the safety of GBCAs and plan to have a public meeting to discuss this issue in the future. Health care providers should limit GBCA use to circumstances in which additional information provided by the contrast agent is necessary, and assess the necessity of repetitive MRIs with GBCAs. Retention of gadolinium affects only GBCAs, and does not apply to other types of scanning agents used for other imaging procedures, such as those that are iodine-based or radioisotopes.</p>\n        <p style=\"text-indent:0em;\">Further information may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery&amp;token=A+6oUwz5nYUZc3lEr1kP7BtLKnUrs6ODZsjcPV9KMyX4JnZOaUZ4v4WHkLmi0EKWvCCQ6RRR7uNYUokCfgeVc768Ba4J+HWDjLlRBCiBxtRZyZ58s7DOgXBX5msP35tg66ICqZf/qPRDl03GsgPnru8Lm2GCbUta4wNEC7od5KHrTCF6F4YU6ugBKJqroXAu&amp;TOPIC_ID=8886\" target=\"_blank\">https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm559709.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708886\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Nephrogenic systemic fibrosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis in patients with impaired elimination of the drugs. Avoid use of gadolinium-based contrast agents in these patients unless the diagnostic information is essential and not available with noncontrast-enhanced magnetic resonance imaging (MRI) or other modalities. Nephrogenic systemic fibrosis may result in fatal or debilitating systemic fibrosis affecting the skin, muscle, and internal organs. The risk for nephrogenic systemic fibrosis appears highest among patients with chronic, severe kidney disease (glomerular filtration rate [GFR] &lt;30 mL/minute/1.73 m<sup>2</sup>), or acute kidney injury.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (eg, &gt;60 years, hypertension, diabetes), estimate the GFR through laboratory testing. For patients at highest risk for nephrogenic systemic fibrosis, do not exceed the recommended gadoteridol dose and allow a sufficient period of time for elimination of the drug from the body prior to any readministration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175126\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Prohance</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22765555\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ProHance</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175129\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent;</li>\n      <li>\n        Gadolinium-Containing Contrast Agent;</li>\n      <li>\n        Radiological/Contrast Media (Nonionic, Low Osmolality);</li>\n      <li>\n        Radiological/Contrast Media, Paramagnetic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3410029\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS imaging:</b> IV: 0.1 mmol/kg (0.2 mL/kg); if needed, a second dose of 0.2 mmol/kg (0.4 mL/kg) may be repeated once within 30 minutes of the first dose </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extracranial/extraspinal tissue:</b> IV: 0.1 mmol/kg (0.2 mL/kg)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50991872\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Risk for NSF development increases as renal function decreases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo 2007). Data has been shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo 2007; Okada 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe 1998; Kuo 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989185\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3410028\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>CNS imaging:</b> IV: Children &ge;2 years and Adolescents: 0.1 mmol/kg (0.2 mL/kg)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112249\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">Children &ge; 2 years and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, use with caution. Risk for nephrogenic systemic fibrosis (NSF) development increases as renal function decreases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: There are no pediatric specific recommendations; based on experience in adult patients, the following has been observed:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo 2007). Data has been shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo 2007; Okada 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe 1998; Kuo 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112250\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175121\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prohance: 279.3 mg/mL (5 mL, 10 mL, 15 mL, 17 mL, 20 mL, 50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175118\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27994112\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;\">ProHance prefilled syringe tip cap contains latex.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3410032\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer as a rapid infusion (10 to 60 mL/minute) or as a bolus (&gt;60 mL/minute). Flush line with NS 5 mL to ensure complete injection of medium. Imaging should be completed within 60 minutes of injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175122\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS imaging:</b> For use in MRI in adults and children &gt;2 years to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine, and associated tissues.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Extracranial/Extraspinal tissues imaging:</b> For use in MRI in adults to visualize lesions in the head and neck.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25474759\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Magnetic resonance angiography (MRA)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5174543\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3410010\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: Gastrointestinal: Nausea (1%), dysgeusia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal cramps, altered mental status, anaphylactoid reaction, anxiety, apnea, ataxia, atrioventricular junctional rhythm, bradycardia, chest pain, cough, cyanosis, deafness (transient), diaphoresis, diarrhea, dizziness, dysphagia, dyspnea, edema, facial edema, fever, flushing, gingivitis, headache, hypertension, hypotension, increased heart rate, injection site reaction, laryngeal edema, laryngismus, loss of consciousness, maculopapular rash, malaise, neck stiffness, nephrogenic systemic fibrosis (NSF/NFD), pain, pain at injection site, paresthesia, prolongation P-R interval on ECG, pruritus, rhinitis, seizure, sialorrhea, skin rash, stare, stupor, syncope, tingling sensation, tinnitus, tongue edema, tongue pruritus, tremor, urinary incontinence, urticaria, vasodepressor syncope, voice disorder, vomiting, watery eyes, wheezing, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3410006\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to gadoteridol or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3410007\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gadolinium retention: Gadolinium is retained for months or years in brain, bone, skin, and other organs (kidney, liver, spleen); the highest concentration and longest duration have been found in the bone. Linear GBCAs (gadodiamide and gadoversetamide &gt; gadoxetate disodium, gadopentetate dimeglumine, and gadobenate dimeglumine) result in more retention than macrocyclic GBCAs (gadoterate meglumine, gadobutrol, and gadoteridol). Pathologic and clinical consequences of gadolinium retention in skin and other organs have been established in patients with impaired renal function; there also have been rare reports of pathologic skin changes in patients with normal renal function. Consequences of gadolinium retention in the brain or in patients with normal renal function have not been established. Patients with normal renal function that may be at higher risk for gadolinium retention include: patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions; take GBCA retention characteristics into consideration for these patients. Minimize repetitive GBCA imaging studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Severe and fatal hypersensitivity reactions, including anaphylaxis, have occurred; appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Delayed reactions may also occur (within several hours of administration). Patients with a history of allergic reactions, drug reactions, or other hypersensitivity-like disorders should be closely observed during and for several hours after the procedure. If hypersensitivity reaction occurs, discontinue gadoteridol immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrogenic systemic fibrosis: <b>[US Boxed Warning]: Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with</b><b> impaired elimination of the drugs<b>; avoid use in these patients unless diagnostic information is essential</b></b> <b>and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. The risk for NSF appears highest in patients with acute kidney injury or chronic, severe renal disease (glomerular filtration rate [GFR] &lt;30 mL/minute/1.73 m<sup>2</sup>). Screen patients for acute kidney injury and other conditions that may reduce renal function; estimate GFR in patients at risk for chronically reduced renal function (eg, diabetes, hypertension, &gt;60 years). For patients at highest risk for NSF, do not exceed the recommended dose and allow a sufficient period of time for elimination of the drug from the body prior to readministration. </b>The risk for NSF appears lower in patients with moderate, chronic renal disease (GFR 30 to 59 mL/minute/1.73 m<sup>2</sup>) and little, if any, in patients with mild, chronic renal disease (GFR 60 to 89 mL/minute/1.73 m<sup>2</sup>). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency following use of gadolinium agents, generally within 48 hours following administration. In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred; risk of acute kidney injury may increase with increasing dose; administer the lowest dose necessary. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: Physicians should be experienced with diagnostic procedures using contrast agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Repeat doses: Repeated procedures have not been studied; safety of sequential doses has only been studied in adults in central nervous system during the same diagnostic session.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299380\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5563034\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8886&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175124\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Gadolinium-based contrast agents cross the placenta; in general, their use in pregnant women is controversial (ACOG 2016). Use should be avoided unless critical for the care of the mother or fetus and it is not prudent to wait until after pregnancy. Agents with a low risk for development of nephrogenic systemic fibrosis should be used at the lowest effective dose (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16353415\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Gadolinium-based contrast agents are present in breast milk (ACR 2015). The manufacturer recommends that caution be exercised when administering gadoteridol to breastfeeding women. Because of the low expected excretion into breast milk and the low absorption from an infant's GI tract, other sources note breastfeeding may be continued without interruption after use (ACOG 2017; ACR 2015). Theoretically, the taste of milk could be altered if it contains contrast media. Women who prefer to temporarily withhold breastfeeding can pump and store milk prior to the procedure and abstain from breastfeeding for 12 to 24 hours (ACR 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3410035\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Signs/symptoms of hypersensitivity (during and for several hours after procedure); renal function (prior to administration and as clinically indicated); signs/symptoms of NSF (during and following procedure); signs/symptoms of acute kidney injury.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3410020\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Gadoteridol is a gadolinium-containing paramagnetic agent. Exposure to an external magnetic field induces a large local magnetic field in exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3410022\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 204 &plusmn; 58 mL/kg; distribution half-life: 0.2 &plusmn; 0.04 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 1.57 &plusmn; 0.08 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (~94%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323165\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Prohance Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">279.3 mg/mL (10 mL): $69.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F175125\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>ProHance (AT, AU, BE, CH, CZ, DE, DK, ES, FI, FR, GB, IE, IT, KR, LU, NL, NO, PL, SE);</li>\n      <li>Prohance (JP, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 9. 2013. Available at http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2013_Contrast_Media.pdf. Accessed September 17, 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG) Committee on Obstetric Practice. Committee Opinion No. 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. <i>Obstet Gynecol</i>. 2017;130(4):e210-e216. doi: 10.1097/AOG.0000000000002355.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoteridol-drug-information/abstract-text/28937575/pubmed\" target=\"_blank\" id=\"28937575\">28937575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Radiology Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.1. http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast%20Manual/2015_Contrast_Media.pdf. Published 2015. Accessed April 15, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control, &ldquo;Nephrogenic Fibrosing Dermopathy Associated with Exposure to Gadolinium-Containing Contrast Agents: St. Louis, Missouri,&rdquo; <i>MMWR Weekly Rep</i>, 2007, 56(07):137-141.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grobner T, &ldquo;Gadolinium - A Specific Trigger for the Development of Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis,&rdquo; <i>Nephrol Dial Transplant</i>, 2006, 21(4):1104-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoteridol-drug-information/abstract-text/16431890/pubmed\" target=\"_blank\" id=\"16431890\">16431890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Joffe P, Thomsen HS, and Meusel M, &quot;Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis,&quot; <i>Acad Radiol</i>, 1998, 5(7):491-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoteridol-drug-information/abstract-text/9653466/pubmed\" target=\"_blank\" id=\"9653466\">9653466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuo PH, Kanal E, Abu-Alfa AK, et al, &quot;Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis,&quot; <i>Radiology</i>, 2007, 242(3):647-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoteridol-drug-information/abstract-text/17213364/pubmed\" target=\"_blank\" id=\"17213364\">17213364</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Okada S, Katagiri K, Kumazaki T, et al, &ldquo;Safety of Gadolinium Contrast Agent in Hemodialysis Patients,&rdquo; <i> Acta Radiol</i>, 2001, 42(3):339-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/gadoteridol-drug-information/abstract-text/11350296/pubmed\" target=\"_blank\" id=\"11350296\">11350296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ProHance Multipack (gadoteridol) [prescribing informationt]. Monroe Twp, NJ: Bracco Diagnostics Inc; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widmark JM, &ldquo;Imaging-related Medications: A Class Overview,&rdquo; <i>Proc(Bayl Univ Med Cent)</i>, 2007, 20(4):408-17.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8886 Version 101.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F49334650\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708886\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F175126\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F22765555\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F175129\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3410029\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50991872\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989185\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F3410028\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51112249\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51112250\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F175121\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F175118\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F27994112\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3410032\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F175122\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25474759\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5174543\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3410010\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3410006\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3410007\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299380\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5563034\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F175124\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F16353415\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3410035\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3410020\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3410022\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323165\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F175125\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8886|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=gadoteridol-patient-drug-information\" class=\"drug drug_patient\">Gadoteridol: Patient drug information</a></li></ul></div></div>","javascript":null}